YD Bio Limited Ordinary Shares (YDES) Stock Score, Valuation & Financial Research

YD Bio Limited Ordinary Shares is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for YDES

YD Bio Limited Ordinary Shares does not currently have a complete Wall Street Score. The stored market price is USD 6.15. These figures are a research snapshot, not a buy or sell recommendation.

What YD Bio Limited Ordinary Shares does

Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

YD Bio Limited operates as a biotechnology company focused on advancing DNA methylation-based cancer detection technology and ophthalmologic innovations. The company utilizes a combined diagnostics platform, clinical service infrastructure, and healthcare commercialization capabilities to develop a scalable operating model across regulated healthcare segments.

Products and services

  • DNA methylation-based cancer detection technology and ophthalmologic innovation products.

Business relationships and partnerships

  • EG BioMed — Collaborated to launch the EG Telehealth Platform on March 31, 2026. Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

YDES financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.15
Market capitalization:
435.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -2.97M
Free cash flow:
USD -8.04M
Cash:
USD 2.66M
Total debt:
USD 5K
EPS:
USD -0.99

What stands out

  • Reported year-over-year revenue growth is -100.0%.
  • Free cash flow is USD -8.04M, negative for the stored period.
  • The balance sheet shows USD 2.66M of cash versus USD 5K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.66M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for YDES

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving YDES's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can YDES fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is YDES likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for YDES to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of YDES's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research YDES

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.